Latest Intelligence on Pharmaceuticals and Healthcare in India

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Are the US and emerging markets ready for the generic drug boom?

One of Barack Obama's key goals as president is to reduce healthcare costs, particularly those related to prescription medications, by increasing the importation of generic drugs. However, the majority of these, or their ingredients, are manufactured in China, and to build confidence in such products, which are often considered unsafe, the FDA will require updated IT systems and solutions.

Published By Datamonitor
17 Nov 2008
CommentWire
CommentWire

AusBiotech 2010: national conference looks to create "global solutions"

AusBiotech 2010, the annual conference of the Australian biotechnology industry, has sought to educate attendees about recent trends in the global pharmaceutical market, and how they can best take advantage of current conditions. This includes exploring opportunities with regional Asia Pacific neighbors, with a potential collaboration between Australia and India one of the key talking points.

Published By Datamonitor
25 Oct 2010
Expert View
Expert View

Big Pharma rushing for foothold in emerging markets despite challenges

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets where recent economic booms have fuelled double-digit growth. However, although the patient potential of these countries is enormous, foreign pharmaceutical companies are currently tapping into only a fraction of the market.

Published By Datamonitor
13 Mar 2008
CommentWire
CommentWire

Cipla: lobbying for more generics in South Africa

Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.

Published By Datamonitor
20 Aug 2002
CommentWire
CommentWire

Daiichi Sankyo: an alternative acquisition strategy

While a number of key Japanese players have hit the product-driven acquisition trail of late, Daiichi Sankyo's proposed offering for generics firm Ranbaxy signals a new strategy, with the cheaper R&D and manufacturing capabilities of the Indian firm representing the key attraction and not product ownership.

Published By Datamonitor
12 Jun 2008
CommentWire
CommentWire

HIV drugs: India clears the path

Published By Datamonitor
12 Sep 2001
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

India: drug seizures dispute settled but concern remains over new trade agreement

The dispute between India and the European Union over recent seizures of Indian-made generics by a number of European countries has been settled before World Trade Organization action. However, Indian drug producers are growing increasingly concerned about the Anti-Counterfeiting Trade Agreement, and that it may allow seizures to become more commonplace.

Published By Datamonitor
12 Oct 2010
CommentWire
CommentWire

India: proposed profit controls threaten pharmaceutical strategy

A new discussion paper from the Indian government has proposed compulsory licensing for patented drugs. While this is unlikely to have a sizable impact given India's track record with patent rejections, the paper also mentions possible profit controls for drugs. These would certainly be more painful and would threaten branded pharmaceutical companies' expansion strategies into emerging markets.

Published By Datamonitor
02 Sep 2010
Expert View
Expert View

Indian pharmaceutical companies: innovative HIV drug reformulations

The FDA has tentatively approved new HIV drug co-formulations combining lamivudine, zidovudine (both originally developed by GSK) and nevirapine (by Boehringer Ingelheim) for use under the PEPFAR program. India's Cipla and Aurobindo, the manufacturers, have showed a remarkable creativity that may eventually pay off in high-price markets like the US and Europe.

Published By Datamonitor
08 Feb 2007

« | 1 | 2 | » »|

No help is available.